Clinical Benefits of Unique Pea Protein Formula for Pediatrics Demonstrated Using Real-World Evidence
Authors: V. Millovich1, G. Lopes2, M. Tyagi2, Z. Cao2, I. Olsen1, and C.J. Valentine1
Research Presented as a Poster at the 2025 Annual Congress for The European Society for Clinical Nutrition and Metabolism (ESPEN)
Population and Design
Retrospective real-world evidence study of 6,422 children (1-17 years) conducted using a closed U.S. claims database with total sample taken from 60 hospitals. Pediatric outpatients with a prescription claim for a nutrition formula were included.
Outcomes Measured
Baseline risk of mortality (Charlson Comorbidity Index), malnutrition, weight loss, GI medication use, any GI intolerance (AGII) symptom score. Outcomes were evaluated by comparing unadjusted descriptive measures of 180 days pre-index and 90 days post-index.
Results
Children in the organic pea protein formula group were sicker at baseline, with a mean Charlson Comorbidity Index score of 0.5 vs. 0.4 in the dairy/soy formula group.
Children prescribed organic pea protein formulas experienced a decrease in GI intolerance vs those on dairy/soy formulas in the 90-day period.
For children on organic pea protein formulas, GI intolerance rate was 17.5% in pre-index and 10.4% in post-index (41% decrease).
For children on dairy/soy formulas, GI intolerance rate was 11.1% in pre-index and 7.2% in post-index (35% decrease).
Children prescribed organic pea protein formulas experienced more improvement in malnutrition vs those on dairy/soy formulas in the 90-day period.
For children on organic pea protein formulas, malnutrition rate was 3.2% in pre-index and 1.4% in post-index period (56.3% improvement).
For children on dairy/soy formulas, malnutrition rate was 1.4% in pre-index and 0.9% in post-index (35.7% improvement).
Read the Full-Text Abstract from ESPEN 2025 Congress
Affiliations:
1. Kate Farms, Goleta, CA, United States
2. Premier Applied Sciences, Inc., Charlotte, NC, United States
Citation:
Millovich V et al., 2025; Clin Nutr ESPEN vol 69, p870, October 2025
Loading form...
We'll have your form in just a moment